Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience
2024

Worsening Suicidal Thoughts After Psilocybin Treatment: A Case Study

Sample size: 1 publication Evidence: low

Author Information

Author(s): Wahba Mourad, Hayes Caroline, Kletter Maartje, McAllister-Williams R. Hamish

Primary Institution: Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle upon Tyne, UK

Hypothesis

Can psilocybin administration lead to adverse events such as increased suicidal ideation in clinical settings?

Conclusion

Psilocybin can temporarily worsen suicidal ideation and cause prolonged adverse events, while also leading to improvements in functional outcomes not captured by depression rating scales.

Supporting Evidence

  • Psilocybin can lead to temporary worsening of suicidal ideation.
  • Participants may experience prolonged adverse reactions following psilocybin experiences.
  • Some patients classified as 'non-responders' can have positive outcomes not reflected in quantitative data.

Takeaway

This study shows that taking psilocybin can make some people feel worse for a while, even if it helps them in other ways later on.

Methodology

The case was summarized and the participant's written account was thematically analyzed and synthesized into a logic model.

Potential Biases

The participant may have guessed she received an active dose, which could affect her reported outcomes.

Limitations

This is a single case report, limiting the generalizability of the findings.

Participant Demographics

The participant had a history of recurrent depression and social anxiety disorder.

Digital Object Identifier (DOI)

10.1192/bjo.2024.768

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication